///////////// Health for all, Hunger for none Q2 2024 Investor Call A u g u s t 0 6 , 2 0 2 4 Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Thes ...

Bayer (BAYRY) announced that it has met the primary endpoint of radiological progression-free survival (rPFS) in its late-stage study evaluating the safety and efficacy of darolutamide in combination with androgen deprivation therapy (ADT) without docetaxelin patients with metastatic hormone-sensitive prostate cancer (mHSPC).The phase III ARANOTE study enrolled 669 patients who were randomized to receive 600mg of darolutamide twice daily or matching placebo in addition to ADT.Per the data readout, the combo ...

Bayer (BAYRY) announced that its wholly owned and independently operating subsidiary, Asklepios BioPharmaceutical, Inc. (AskBio), initiated recruitment in the mid-stage study REGENERATE-PD. REGENERATE-PD is a phase II study evaluating the efficacy and safety of AB-1005, an investigational adeno- associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. Subjects will receive either bilateral image-guided infusion of AAV2 ...

Bayer AG (BAYRY) reported first-quarter 2024 core earnings of 77 cents per American Depositary Receipt (ADR). The company reported earnings of 79 cents per ADR in the year-ago quarter. Core earnings of €2.82 per share declined 4.4% year over year. Total sales in the reported quarter were $14.95 billion (€13.77 billion), down 4.3% on a reported basis. On a currency and portfolio-adjusted basis, sales declined 0.6% year over year. All growth rates mentioned below are on a year-over-year basis after adjusting ...

Bayer AG (BAYRY) announced positive top-line results of the phase III study, OASIS 3, evaluating the efficacy and long-term safety of pipeline candidate elinzanetant compared to placebo. Elinzanetant, a dual neurokinin-1,3 (NK-1,3) receptor antagonist, is in late-stage clinical development for the non-hormonal treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, administered orally once daily. OASIS 3 is the third phase III study in the OASIS clinical development program. The ...

Bayer AG (BAYRY) reported fourth-quarter 2023 core earnings of 50 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 45 cents. The company reported earnings of 34 cents per ADR in the year-ago quarter. Core earnings of €1.85 per share rose 37% year over year in the fourth quarter of 2023. Total sales in the reported quarter were $12.77 billion (€11.86 billion), down 1.2% on a reported basis. On a currency and portfolio-adjusted basis, sales rose 5.5% year over year. All ...

Bayer与BridgeBio合作 - Bayer宣布从BridgeBio获得了acoramidis在欧洲的独家营销权[1] - Acoramidis是一种正在研究的下一代口服高效小分子稳定剂，用于治疗患有transthyretin淀粉样心肌病（ATTR-CM）的患者[2] - Acoramidis在安慰剂对照的III期研究中达到了所有临床终点，显著减少了住院负担，改善了患者的生存率，并保留了功能能力和生活质量[3] Bayer的合作与支付 - Bayer向BridgeBio和关联公司支付了3.1亿美元的前期款项，同时还有近期里程碑付款、额外的未公开销售里程碑付款和起始在30%左右的分层版税[5] - Bayer拥有心血管药物Xarelto，而acoramidis的加入将为公司的产品组合带来助力，一旦获批，acoramidis将与Pfizer的Vyndaqel竞争[6] 公司排名和展望 - Bayer此前停止了研究OCEANIC-AF，原因是asundexian的疗效不及直接口服抗凝药Eliquis，这是一个重大挫折[9] - Bayer目前的Zacks排名为4（卖出），而ADMA Biologics的排名为1（强烈买入）[11][12] - ADMA Biologics在过去的30天里，2024年每股收益的Zacks共识预期增加了8美分至22美分，2025年每股收益的共识预期为50美分[13]

欧洲央行利率决定 - 欧洲央行将发布本年度第二次利率决定，欧洲 Stoxx 600 指数受到关注[1] - 预计欧洲央行将维持利率不变，但可能暗示未来几个月会降息[2] - 欧洲通胀下降速度超出预期，服务业通胀仍然高企[5] Stoxx 600 指数展望 - Stoxx 600 指数在过去几个月呈现强劲上涨趋势，技术面展望看涨[11] - Stoxx 600 指数已突破重要阻力点，下一个关注点在 €525[12] - Stoxx 600 指数成分公司中大多数今年股价大幅上涨[9]

拜耳股息削减计划 - 拜耳宣布计划在未来三年内将股息削减95%，以应对与其收购孟山都公司相关的债务[1][2][4] - 拜耳表示，将按照德国法律规定的最低标准向投资者支付股息，2023年每股支付12美分，低于去年的2.60美元[3][10] - 自收购以来，拜耳还被埋在法律费用和不断上升的利率中，据彭博社获得的最新文件显示，债务总额接近420亿美元[5]

Bayer AG (BAYRY) announced plans to cut its dividend rate for 2023. Following a review of the company’s capital allocation priorities to reduce debt, BAYRY plans to amend its dividend policy to pay out only the legally required minimum for three years. Consequently, the decision will reduce the dividend to €0.11 per share for 2023 compared with €2.40 in 2022. This proposal comes as the company faces a high level of debt, coupled with high-interest rates and a challenging free cash flow situation. The ongoin ...